Company: CERO
Filing Date: 2025-08-22
Form Type: 10-Q
Source: 0001213900-25-079898
Chunk: 211

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-08-22
Form: 10-Q
Item: Item 8
Chunk 211
---
decessor and Successor)  
    Difference  
    Percentage Change 
  
    Operating expenses: 

    Research and development 
    $5,661,790  
    $4,382,551  
    $1,279,239  
     29.2%
  
    General and administrative 
     4,012,532  
     5,317,756  
     (1,305,224) 
     (24.5)%
  
    Total operating expenses 
     9,674,322  
     9,700,307  
     (25,985) 
     (0.3)%
  
    Loss from operations 
     (9,674,322) 
     (9,700,307) 
     (25,985) 
     (0.3)%

    Other income (expense): 

    Gain from settlement of liabilities with vendor 
     -  
     589,223  
     (589,223) 
     (100.0)%
  
    Other expenses 
     -  
     (630,775) 
     630,775  
     (100.0)%
  
    Change in fair value of derivative liabilities and earnout liabilities 
     -  
     5,020,117  
     (5,020,117) 
     (100.0)%
  
    Share-based inducement expense 
     (863,550) 
     -  
     (863,550) 
     (100.0)%
  
    Interest income (expense), net 
     14,626  
     (26,606) 
     41,232  
     155.0%
  
    Total other income (expense), net 
     (848,924) 
     4,951,959  
     (5,800,883) 
     (117.1)%

    Net loss 
     (10,523,246) 
     (4,748,348) 
     (5,774,898) 
     121.6%
  
    Deemed dividend on Series A, B and C Preferred Stock 
     (24,964,518) 
     -  
     (24,964,518)